Bone Marrow News and Research RSS Feed - Bone Marrow News and Research

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.
Hydrogen sulfide regulates bone marrow mesenchymal stem cells, shows study

Hydrogen sulfide regulates bone marrow mesenchymal stem cells, shows study

Stem cells in bone marrow need to produce hydrogen sulfide in order to properly multiply and form bone tissue, according to a new study from the Center for Craniofacial Molecular Biology at the Herman Ostrow School of Dentistry of USC. [More]
Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* 'orphan drug designation' for the treatment of patients with acute myeloid leukaemia (AML). [More]

Harvard successfully transplants regenerated esophagus into rat using bioreactor

Harvard Apparatus Regenerative Technology, Inc., a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces that a research team led by Paolo Macchiarini, MD, PhD at Karolinska Institutet in Sweden has successfully transplanted a regenerated esophagus into a rat using a bioreactor developed by HART. [More]
Nanotechnology unlocks new pathways for targeted drug delivery

Nanotechnology unlocks new pathways for targeted drug delivery

​Significant advances have been made in chemotherapy over the past decade, but targeting drugs to cancer cells while avoiding healthy tissues continues to be a major challenge. [More]
BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study. [More]
Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China. [More]

Red LED irradiation promotes cell transplantation in treatment of hypoxic-ischemic brain damage

A series of previous studies suggested that the neuronal differentiation rate of bone marrow mesenchymal stem cells during the in vitro culture reached 78-92%, but their in vivo transplantation efficiency, and survival and differentiation rates were very low. [More]

Stem cells culled from bone marrow may prove beneficial in stroke recovery

Stem cells culled from bone marrow may prove beneficial in stroke recovery, scientists at UC Irvine's Sue & Bill Gross Stem Cell Research Center have learned. [More]
Researchers receive NIH grant for pediatric acute myelogenous leukemia treatment

Researchers receive NIH grant for pediatric acute myelogenous leukemia treatment

​A $1.92 million grant from the National Institutes of Health (NIH) was awarded to a research team that focuses on new approaches for treatment of relapsed pediatric acute myelogenous leukemia (rAML), led by Yang Liu, PhD, Bothworth Chair and Director of the Center for Cancer and Immunology Research (CCIR) at Children's Research Institute of Children's National Health System, and Reuven Schore, MD, member of CCIR and attending physician in the Leukemia & Lymphoma Program of the Division of Oncology of the Center for Cancer and Blood Disorders. [More]

Researchers identify experimental drugs to block treatment-resistant leukemia

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. [More]
Bezos family gifts $20M to Fred Hutchinson scientists for development of novel cancer immunotherapies

Bezos family gifts $20M to Fred Hutchinson scientists for development of novel cancer immunotherapies

​Fred Hutchinson Cancer Research Center scientists striving for new cancer cures - and the patients who stand to benefit from them - got an enormous boost today when the Bezos family committed $20 million to support the development of novel cancer immunotherapies. It is the largest single contribution in Fred Hutch's history. [More]

Scientists battle against cancer with nanoballoons and lasers

Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go. [More]
Study looks at ability of nontoxic molecules to store harmful alpha emitting radioisotopes

Study looks at ability of nontoxic molecules to store harmful alpha emitting radioisotopes

Researchers have discovered that microscopic "bubbles" developed at Kansas State University are safe and effective storage lockers for harmful isotopes that emit ionizing radiation for treating tumors. [More]
FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer. [More]
Cedars-Sinai earns grant to conduct clinical trial of gene therapy product for patients with Lou Gehrig's disease

Cedars-Sinai earns grant to conduct clinical trial of gene therapy product for patients with Lou Gehrig's disease

The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS. [More]

Research uncovers link between diet and blood cell markers of heart attack associated inflammation

New research further illuminates the heart-healthy benefits of the Mediterranean diet, tying the eating plan to lower levels of platelets and white blood cells, two markers of inflammation. Inflammation has an association with greater risk of heart attack and stroke. [More]

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]
Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed. [More]
Two pediatricians win March of Dimes/Col. Harland D. Sanders Lifetime Achievement Award in Genetics

Two pediatricians win March of Dimes/Col. Harland D. Sanders Lifetime Achievement Award in Genetics

Two pediatricians whose research led to the need for early identification of and treatment of severe combined immunodeficiency (SCID) and its inclusion in newborn screening have received the March of Dimes/Col. Harland D. Sanders Lifetime Achievement Award in Genetics. [More]

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the final results from its Phase I/IIa, open-label study in patients with refractory or relapsed multiple myeloma (MM). [More]